Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAA Therapy in HCV+ Donor to HCV- Recipient Lung Transplant
NCT03625687Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2019
- Primary completion
- Apr 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glecaprevir and velpatasvir in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Primary endpoint: Undetectable Blood HCV RNA Level. Started Feb 2019; status: terminated.
02
Drugs
glecaprevirvelpatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03625687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625687.